Last updated: October 14, 2026
Pharmacyclics LLC v. Alvogen Pine Brook LLC, No. 1:19-cv-00434, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware concerning Alvogen’s abbreviated new drug application for a generic version of Imbruvica, whose active ingredient is ibrutinib. Pharmacyclics asserted Orange Book-listed patents covering ibrutinib and related therapeutic uses. The case ended without a publicly reported trial judgment on infringement or validity. The parties’ resolution restricted Alvogen’s commercial launch under confidential settlement terms.
What drug and ANDA were at issue in Pharmacyclics v. Alvogen?
The case concerned ibrutinib, the active pharmaceutical ingredient in Imbruvica. Imbruvica is marketed by Pharmacyclics, a subsidiary of AbbVie, together with Janssen Biotech.
Ibrutinib is a covalent Bruton’s tyrosine kinase inhibitor approved for several hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström’s macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease. The product has been marketed in capsule and tablet dosage forms under FDA-approved New Drug Applications 205552 and 210563. (FDA, 2024a, 2024b)
Alvogen’s filing of an ANDA created the statutory basis for suit under 35 U.S.C. § 271(e)(2). The complaint alleged that filing the ANDA, together with Alvogen’s proposed manufacture, use and sale of generic ibrutinib, infringed patents listed for Imbruvica.
Case profile
| Item |
Details |
| Case |
Pharmacyclics LLC v. Alvogen Pine Brook LLC |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:19-cv-00434 |
| Filing date |
2019 |
| Plaintiff |
Pharmacyclics LLC |
| Defendant |
Alvogen Pine Brook LLC |
| Technology |
Ibrutinib |
| Branded product |
Imbruvica |
| Legal pathway |
Hatch-Waxman ANDA litigation |
| Disposition |
Resolved by settlement and dismissal |
| Public merits judgment |
No reported final infringement or validity judgment |
What patents protected Imbruvica in the Alvogen litigation?
The asserted patent group centered on patents directed to ibrutinib and its pharmaceutical use. Public patent records identify the principal Imbruvica composition patent as U.S. Patent No. 8,754,090. Related continuation patents, including U.S. Patent Nos. 9,458,157 and 9,926,367, also formed part of the broader ibrutinib patent estate and were relevant to generic challenges.
Principal patent estate
| Patent |
General subject matter |
Patent term information |
| U.S. Patent No. 8,754,090 |
Ibrutinib compound and related compounds |
Public Orange Book records identify an expiration date in March 2032 |
| U.S. Patent No. 9,458,157 |
Related ibrutinib compound claims and continuation subject matter |
Public records identify an expiration date in March 2032 |
| U.S. Patent No. 9,926,367 |
Related pharmaceutical and compound claims |
Public records identify an expiration date in March 2032 |
| Later Imbruvica patents |
Additional formulations, dosing regimens and methods of treatment |
Expirations vary by patent and indication |
The specific patents asserted against Alvogen must be distinguished from the entire Imbruvica portfolio. A branded company may list numerous patents in the Orange Book, but a particular ANDA action typically involves only the patents identified in the complaint and later amended pleadings.
What was the legal basis of Pharmacyclics’ claims?
Pharmacyclics’ claims arose from Alvogen’s Paragraph IV certification. A Paragraph IV certification states that a patent listed for the reference product is invalid, unenforceable or will not be infringed by the proposed generic product.
The ANDA filing is treated as an artificial act of infringement under Section 271(e)(2). The litigation therefore could proceed before commercial marketing of Alvogen’s product. Pharmacyclics sought the standard Hatch-Waxman remedies, including a declaration of infringement and an order preventing commercial launch until expiration of the relevant patents.
The case presented the usual patent issues for a small-molecule oncology drug:
- Claim construction for chemical and pharmaceutical terms.
- Literal infringement and infringement under the doctrine of equivalents.
- Anticipation and obviousness under 35 U.S.C. §§ 102 and 103.
- Written description and enablement.
- Patent term, terminal disclaimers and Orange Book listing issues.
- The scope of any settlement-based launch date.
No publicly reported decision in this action resolved those issues on the merits.
How did the Alvogen litigation end?
The action was resolved through settlement rather than a reported trial verdict. The publicly available docket reflects dismissal of the litigation, but the commercial terms of the settlement were not publicly disclosed in the court’s termination entry.
The absence of a merits judgment has several consequences:
- The court did not issue a public finding that the asserted patents were valid.
- The court did not issue a public finding that Alvogen’s proposed product infringed.
- The settlement did not create binding precedent for other generic defendants.
- The launch date, royalty structure, authorized-generic terms and supply provisions cannot be inferred from the dismissal alone.
- Other generic applicants remained free to pursue separate Paragraph IV challenges.
A confidential settlement can still have substantial commercial effect. If the agreement granted Alvogen a future launch date, it would convert the litigation risk into a negotiated market-entry timetable. If the agreement included a license or authorized-generic arrangement, it could reduce the practical value of a later independent patent victory by another challenger.
What was the Orange Book status of Imbruvica?
Imbruvica has had multiple Orange Book-listed patents covering the active ingredient, formulations and approved methods of use. The Orange Book does not itself determine whether a listed patent is valid or infringed. It records the sponsor’s patent certifications and provides the framework for abbreviated-application litigation. (FDA, 2024c)
The relevant Orange Book questions in the Alvogen case were:
- Which patents were listed against the ibrutinib reference product?
- Which patents did Alvogen challenge with a Paragraph IV certification?
- Whether Pharmacyclics filed suit within the 45-day statutory period.
- Whether the litigation triggered a 30-month stay of FDA approval.
- Whether the final settlement allowed an earlier launch than the listed patent expiry dates.
A 30-month stay blocks FDA approval during the statutory period unless the court enters an earlier decision or the stay is otherwise terminated. The stay does not necessarily prevent a generic company from preparing for launch, and it does not itself establish patent validity.
What formulations and methods of use were protected?
The ibrutinib estate included more than the basic chemical compound. Relevant protection categories included:
Compound claims
Compound patents protect ibrutinib itself and chemically related structures. These claims generally provide the broadest protection against an ordinary generic product containing the same active ingredient, subject to validity and patent-term limitations.
Pharmaceutical composition claims
Composition claims may cover ibrutinib combined with pharmaceutically acceptable excipients, defined dosage forms or specified concentration ranges. These claims can create separate infringement issues if the generic applicant proposes a formulation materially different from the branded product.
Tablet and capsule formulations
Imbruvica has been marketed in capsules and tablets. Formulation patents may address dissolution, stability, excipient selection, particle size, solid-state properties or manufacturing processes. A generic applicant can reduce formulation exposure by designing a non-infringing formulation, but the active-ingredient patent remains the principal barrier while enforceable.
Method-of-use claims
Method patents cover treatment of specific diseases or patient populations. A generic applicant can attempt a section viii statement carving out patented indications from its label. That strategy is less effective where the product has substantial unpatented uses or where the proposed label still encourages use of the patented method.
When does generic ibrutinib lose exclusivity?
The principal publicly identified composition patents for ibrutinib had March 2032 expiration dates in Orange Book records. Those dates are more important than the nominal 30-month litigation stay because a settlement or final judgment can alter the practical launch date.
The effective generic-entry timeline can include:
| Event |
Commercial effect |
| NDA approval |
Establishes the branded reference product |
| Orange Book listing |
Identifies patents for ANDA certification |
| Paragraph IV notice |
Creates potential litigation |
| 30-month stay |
Delays FDA approval in qualifying circumstances |
| Patent settlement |
May establish an agreed launch date |
| Patent expiration |
Removes the relevant patent barrier |
| Pediatric exclusivity |
Can add six months where granted |
| Regulatory exclusivity |
May restrict approval independently of patents |
Patent expiry does not automatically guarantee immediate generic sales. FDA approval status, manufacturing readiness, supply agreements, controlled launch provisions and separate patents can affect entry.
Which companies challenged the ibrutinib patent estate?
Alvogen was one of several generic-drug companies to pursue ibrutinib opportunities. The broader competitive field included companies that filed ANDAs or engaged in patent litigation involving Imbruvica patents. Publicly reported cases involving other challengers have included disputes concerning Teva and additional generic manufacturers.
Each case must be analyzed separately. A settlement with Alvogen did not eliminate the patent rights against other ANDA filers and did not adjudicate the validity of the ibrutinib patents for the industry as a whole.
The principal competitive risks were:
- Multiple Paragraph IV filers creating potential first-filer dynamics.
- A successful invalidity decision in a separate case.
- A non-infringing formulation that avoided selected formulation patents.
- An authorized-generic launch by the branded company.
- Label carving for patented indications.
- Settlement agreements producing staggered generic launch dates.
How strong was the Pharmacyclics patent estate?
The estate was commercially strong because it combined compound protection with continuation patents, formulation coverage and method-of-use claims. The ibrutinib compound patent was the central barrier. A successful invalidity ruling against that patent would have materially reduced the estate’s ability to delay generic entry, even if formulation and method patents remained in force.
The estate also had structural advantages:
- A single active ingredient supported multiple indications.
- The product had significant oncology revenue exposure.
- The branded product had both capsule and tablet presentations.
- Orange Book listings created a litigation mechanism for each qualifying ANDA.
- Continuation practice extended claim diversity across the product lifecycle.
Its principal weakness was litigation concentration. A small number of foundational patents can carry most of the commercial value. If a court invalidates or narrows those patents, later formulation and method patents may provide narrower protection.
What revenue exposure did the settlement address?
Imbruvica was a major commercial product for AbbVie and Janssen. AbbVie reported Imbruvica revenue of approximately $4.4 billion in 2023, with sales affected by competition, indication mix and the broader hematologic oncology market. (AbbVie, 2024)
A generic ibrutinib launch would place pressure on:
- Net price and gross-to-net realization.
- U.S. prescription volume.
- Payer formulary positioning.
- Oncology distribution contracts.
- Use in chronic treatment settings.
- Revenue from mature indications with limited remaining exclusivity.
The business effect of an Alvogen settlement depended primarily on the negotiated launch date and whether the agreement preserved a high-value branded market through the core patent period.
What litigation and settlement risks remain?
The case itself ended without a public merits ruling, so it did not resolve the principal validity questions for the ibrutinib estate. Remaining risks included:
- Separate challenges by other generic manufacturers.
- Federal Circuit decisions in related ibrutinib patent cases.
- Orange Book delisting or listing disputes.
- New formulation or method patents.
- Antitrust scrutiny of settlement terms.
- Earlier-than-expected entry under a later settlement.
- FDA approval of a generic product after patent or exclusivity barriers lapse.
Manufacturing risk was less significant than for a biologic because ibrutinib is a small molecule. The main intellectual-property barriers were chemical synthesis, formulation design, regulatory certification and patent enforcement, rather than biosimilar comparability or reference-product manufacturing access.
Is there biosimilar risk for Imbruvica?
No. Imbruvica is a small-molecule drug approved under the NDA pathway, not a biologic licensed under the Public Health Service Act. The relevant competitive threat is generic ibrutinib through an ANDA, not a biosimilar through a 351(k) application.
This distinction affects:
- Approval standards.
- Patent certifications.
- Interchangeability rules.
- Substitution at the pharmacy level.
- Regulatory exclusivity.
- Litigation timing.
Key Takeaways
- Pharmacyclics v. Alvogen was a Hatch-Waxman case involving generic ibrutinib and Imbruvica.
- The action was filed in the District of Delaware as No. 1:19-cv-00434.
- Pharmacyclics relied on the ibrutinib patent estate, including compound and related continuation patents.
- The case ended through settlement and dismissal, without a public merits ruling.
- Settlement terms and any agreed Alvogen launch date were not publicly disclosed in the termination record.
- The principal ibrutinib patent barrier identified in Orange Book records extended into March 2032.
- Generic, rather than biosimilar, competition is the relevant market risk.
- The case did not determine the validity of the Imbruvica patent estate for other generic challengers.
FAQs
Did Alvogen receive FDA approval for generic ibrutinib?
The case docket does not establish the timing or final status of any FDA approval for Alvogen’s ANDA. FDA approval status must be assessed separately from the patent litigation record.
Was Pharmacyclics v. Alvogen decided by a jury?
No public jury verdict or bench trial judgment resolved the case. The action ended through settlement and dismissal.
Did the Alvogen settlement invalidate any Imbruvica patent?
No. A private settlement and dismissal do not invalidate a patent and do not constitute a public judicial determination of patent validity.
Could another generic company launch ibrutinib before March 2032?
Yes, if it obtained a judgment of invalidity or non-infringement, reached a license or settlement permitting earlier entry, relied on a non-listed patent position, or otherwise satisfied FDA and patent-law requirements.
Is Imbruvica protected by a biosimilar exclusivity period?
No. Imbruvica is a small-molecule NDA product. Its competitive exclusivity analysis is based on generic-drug rules, Orange Book patents and NDA exclusivity, not biosimilar exclusivity.
References
-
AbbVie Inc. (2024). 2023 annual report. AbbVie.
-
U.S. Food and Drug Administration. (2024a). Imbruvica (ibrutinib) capsules, prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024b). Imbruvica (ibrutinib) tablets, prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. District Court for the District of Delaware. (2019). Pharmacyclics LLC v. Alvogen Pine Brook LLC, No. 1:19-cv-00434.
-
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,754,090: Substituted phenoxy phenyl derivatives. USPTO.
-
U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,458,157. USPTO.
-
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,926,367. USPTO.
